TGR-1202 + brentuximab vedotin
TGR-BV-107
Phase 1 small_molecule completed
Quick answer
TGR-1202 + brentuximab vedotin for Hodgkin's Lymphoma is a Phase 1 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TG THERAPEUTICS, INC.
- Indication
- Hodgkin's Lymphoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed